All In Biotech

Drug Trial Radar · NCT01324128

A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients

An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 Compared With Sevelamer Carbonate Followed by a Randomised Comparison of PA21 Maintenance Dose Versus PA21-Low Dose in Dialysis Patients With Hyperphosphataemia

Last checked: Nov 20, 2026Latest source record: Apr 24, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,059 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,059

Actual

Start

Mar 2011

Primary completion

Apr 2012

Study completion Oct 2012

Sponsor

Lead sponsor
Vifor PharmaIndustry
Sponsor type
Industry
Collaborators
Fresenius Medical Care North America
First posted
Mar 28, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, randomised, active controlled, multicentre study to investigate the safety and efficacy of PA21, a phosphate binder, for control of hyperphosphataemia in dialysis patients. The primary objective is to establish the efficacy of PA21 for lowering phosphate levels in these patients.

Conditions

  • Chronic Kidney Disease Requiring Chronic Dialysis

Interventions

  • PA21 (2.5 g tablet containing 500 mg iron)Drug

    Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).

  • Sevelamer carbonateDrug

    Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day)

  • PA21-1 (1.25 g tablet containing 250 mg iron)Drug

    Low dose comparator (1.25 g/day)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Serum Phosphorus Levels From Week 24 to Week 27Time frame: Week 24, Week 27

Locations

15 sites in 15 countries. Site status is shown where the registry gives one.

  • Site not named

    San Antonio, Texas

  • LKH St. Polten

    Sankt Pölten, Austria

  • CHU Sart Tilman

    Liège, Belgium

  • Clinical Hospital Center Rijeka

    Rijeka, Croatia

  • Dialysis Centre Fresenius Medical Care

    Sokolov, Czechia

  • KfH Nierenzentrum Berlin-Neukoelln

    Berlin, Germany

  • Vidzemes Hospital

    Valmiera, Latvia

  • Vilnius University Hospital Santariskiu Clinics

    Vilnius, Lithuania

  • Teaching Hospital no.1 of Medical University of Lodz

    Lodz, Poland

  • Dialmed Clinic SRL

    Sibiu, Romania

  • City Mariinsky Hospital

    Saint Petersburg, Russia

  • Zvezdara Clinical Medical Center

    Belgrade, Serbia

  • Lakeview Hospital

    Benoni, South Africa

  • Mykolayiv Regional Hospital

    Mykolayiv, Ukraine

  • Dorset County Hospital NHS Foundation Trust

    Dorset, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.